- Rating
- 3
- Confidence
- 4
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper introduces MuCO2, a framework for generating conformations of noncanonical cyclic peptides. It extends MuCO with aligned Uni-Mol2 and ESM-2 representations, modification-aware quaternion flow, and curriculum learning, together with a structure-guided Feynman–Kac steering strategy for backbone selection. Empirically, the authors report competitive performance across canonical and noncanonical cyclic-peptide benchmarks, with improvements in cyclization success and residue-level chirality preservation, particularly for chemically modified peptides.
Critical strengths
The paper addresses a meaningful and well-motivated problem. Noncanonical cyclic-peptide conformation generation is a relevant application area with genuine modeling challenges arising from ring-closure constraints, limited structural data for modified residues, and diverse stereochemical and side-chain modifications. The paper identifies a plausible and relevant tension between retaining canonical conformational priors and accommodating noncanonical chemistry. This framing is clear and helps motivate the architecture.
The method is conceptually coherent and reasonably well aligned with the problem structure. The decomposition into backbone generation, side-chain assembly, and physical refinement is intuitive. The chemical alignment mechanism is intended to accommodate residues outside the canonical vocabulary, while modification-aware conditioning introduces methylation and stereochemical information. The use of residue-level and pairwise representations as conditioning information is a sensible design for noncanonical cyclic-peptide generation. The overall architecture in Fig. 1 is understandable and the components form a coherent high-level pipeline.
The empirical section is comparatively broad. The paper evaluates on multiple benchmarks and reports several complementary metrics, including cyclization success, vacuum and implicit-solvent energy scores, backbone RMSD, and residue-level chirality preservation. This breadth is a strength. The ablation study is useful because it provides initial evidence about the contributions of backbone parameterization, curriculum training, and chemical representations. The external MeD and mixed-modification evaluations also support the claimed motivation beyond performance on canonical peptides.
Presentation of the overall framework is generally clear. The paper is organized around the main modules, the overview figure is informative, and the high-level generation process is easy to follow. The distinction between backbone generation, hybrid side-chain assembly, and force-field refinement is presented clearly. The method sections are organized around the core components and the experiments are reasonably well structured.
The contribution is potentially useful within a specialized but relevant area. Even if the scope is domain specific, extending cyclic-peptide models to accommodate chemical and stereochemical modifications can be practically meaningful. The paper also presents ideas, particularly chemical representation transfer and physics guided data augmentation, that may inform broader molecular conformation-modeling problems.
Critical weaknesses
The novelty is limited and not fully convincing as a major conceptual advance. While the full framework is reasonably well assembled, many of the ingredients are individually familiar, including hierarchical conformation generation, pretrained molecular representations, quaternion flow, template assembly, and force-field refinement. The paper’s main originality appears to lie in extending MuCO to noncanonical chemistry through the combination of chemical alignment, curriculum learning, and structure-guided selection. That can still be valuable, but the paper should do more to clarify precisely what is fundamentally new relative to prior cyclic-peptide generators and simpler adaptations of the existing framework.
The theoretical section is weaker than the empirical section. The analysis in Appendix C appears to provide a formal description and heuristic justification of FKS rather than a tightly algorithm specific demonstration of its claimed advantages. Based on the current presentation, it is not fully clear how geometric dispersion guarantees distinct physical-basin coverage or improved low-energy discovery. The DPP approximation and near-optimal dispersion claims also lack clearly defined approximation guarantees. I do not view the absence of a universal guarantee as a fatal flaw, but the theory currently reads as supportive intuition rather than central evidence.
The empirical comparisons are broad but still leave some important questions open. The paper compares against a useful set of learned baselines, but it is not fully clear whether relevant conventional conformer generation methods and other generative approaches are adequately represented under comparable computational budgets. Because the framework introduces several interacting components, I would like more detail on fairness of sampling and training budgets. In particular, main table inference uses (K=K_0), so FKS retains all proposed backbones, while its dedicated ablation increases the proposal pool from 10 to 100. Curriculum rounds also change data and training budget simultaneously, making the individual mechanisms difficult to isolate.
The practical significance of the contribution is somewhat uncertain. The paper presents the method as an efficient and generalizable framework for noncanonical cyclic-peptide sampling, but the experimental evidence is concentrated on structural and force-field-based metrics, with pseudo label generation, refinement, and energy evaluation all relying on CHARMM36. That is acceptable for an initial computational study, but it weakens the case for practical scientific significance unless the authors demonstrate a clear cost quality advantage over conventional tools, improved agreement with independent experimental data, or a useful downstream application. The absence of end-to-end runtime measurements particularly limits the claimed efficiency advantage.
Some claims are stronger than the available evidence strictly supports. The paper occasionally presents FKS as ensuring distinct basin exploration and the overall pipeline as providing near-perfect stereochemical preservation. However, cyclization success and residue level chirality averages do not directly establish complete molecular validity or accurate conformational distributions. Given the available evidence, more measured claims would be preferable. Several details also require clarification, including the whole peptide versus residue wise feature switch, the different side-chain partitions used in the main text and appendix, and the aggregation of dataset level energy results. These inconsistencies make the actual implementation and reported improvements harder to assess.
Questions for authors
What are the closest prior methods to MuCO2 in terms of noncanonical cyclic-peptide generation, and what is the minimal technical delta? A sharper comparison with MuCO and other compatible generators would help assess originality.
How fair are the comparisons in terms of sampling budget, training effort, and computational cost? Please provide end-to-end timing and compare FKS with random or simple diversity-based selection from the same candidate pool, alongside budget matched curriculum controls.
How directly does the analysis in Appendix C apply to the actual FKS sampling rule and subsequent force-field relaxation? Does it formally establish improved physical basin coverage or low-energy discovery relative to random selection, or mainly provide a conceptual justification?
How robust are the physical validity conclusions to the evaluation protocol? Since cyclization success and residue level chirality measure different aspects, please clarify complete molecule stereochemical validity, failure handling, and energy aggregation.
To what extent does MuCO2 provide practical benefits beyond improved scores under the shared CHARMM36 pipeline? Could the approach demonstrate a clear cost quality advantage over conventional conformer generation tools, improved experimental agreement, or a useful downstream application?
7 comments
[Response to W1 & Q1] Conceptual Novelty and Technical Delta Over MuCO
While MuCO (Wang et al., 2026; Page 14, Line 706) established a multi-stage paradigm, it is strictly restricted to canonical cyclic L-peptides and collapses on noncanonical chemistry. MuCO2 introduces three minimal, non-trivial technical contributions to overcome these fundamental physical barriers:
- Cross-Modal Chemical Alignment Adapter (, Eq. 2, Page 4): ESM-2 cannot encode ncAAs. We bridge frozen Uni-Mol2 atomic representations into the residue trunk. As shown in Table 14 (Page 38), removing this alignment and relying on sequence-only representations causes chirality preservation to plummet by 6.06% and degrades implicit water score by 56.47 kJ/mol on CycPeptMPDB-Mixed.
- Singularity-Free Quaternion Flow with Parity Conditioning (Eqs. 4 & 5, Pages 4–5): Standard Riemannian SE(3) flow matching on suffers from numerical instabilities and chiral collapse under inversion. We formulate the flow on via SLERP, gated by directional peptide-bond indicators () and relational parity (). On CycPeptMPDB-MeD, this boosts
Success@1from 42.13% to 67.90% and chirality preservation from 78.37% to 89.21% (Table 10, Page 36). - Symmetry-Driven Physics Curriculum (Algorithm 1, Page 6; Algorithm 2, Page 23): Solves the extreme data scarcity of multi-modified macrocycles. Without this curriculum,
Success@10on CPSea-MeD drops from 84.10% to 28.06% (Table 12, Page 37).
[Response to W2 & Q3] Theoretical Framing vs. Empirical Role of Feynman-Kac Steering (FKS)
We appreciate the reviewer's insight regarding theoretical guarantees versus physical realities. We agree that geometric dispersion does not unconditionally guarantee entry into distinct force-field local minima. We have explicitly clarified in Appendix C.3 (Page 27, Lines 1412–1414) that FKS provides an exploratory inductive bias motivated by extreme-value statistics (Eq. 25): by preventing sample degeneracy at the continuous flow stage, it enlarges the union volume of explored basins (, Eq. 26), elevating closer to the nominal budget .
Empirically, under an identical evaluation budget of 100 full-atom candidates on CPSea-PDB (Figure 4e, Page 10), FKS drives down vacuum energy by 43.71 kJ/mol and implicit water score by 40.41 kJ/mol, while lowering -RMSD from to over unsteered naive tree expansion. Figure 7 (Page 38) further confirms that FKS introduces negligible time overhead relative to downstream relaxation.
[Response to W3 & Q5] Comparison with Conventional Conformer Tools and Curriculum Rationale
- Failure Modes of Conventional Distance Geometry: Standard distance geometry tools (such as RDKit ETKDG) fail to close macrocyclic rings under dense backbone constraints. In our tests, ETKDG achieved near-zero valid cyclization for macrocycles longer than 10 residues.
- Prohibitive Cost of Physics-Based Search Protocols: Comprehensive sampling tools like CREST are computationally prohibitive for high-throughput discovery: CREMP reports an average runtime of 13.9 hours on 14 CPU cores (195 CPU-hours) per single cyclic hexapeptide, totaling 3.9 million CPU-hours across their dataset (Grambow et al., 2024; Page 12, Line 628). Moreover, incorporating novel ncAAs into Rosetta/MD incurs tedious parameterization bottlenecks for charges and bonded terms (Wijesiri & Brown, 2025; Page 14, Line 713). MuCO2 provides an amortized deep generative alternative that evaluates in seconds.
- Curriculum Training Fairness (Table 12, Page 37): In our experiments, extending Round-1 training on single-site modifications did not improve generalization to multi-site peptides; instead, it led to severe overfitting on isolated modifications. Progressive expansion across Rounds 1–3 is physically necessary: earlier rounds generate viable geometric starting points that allow CHARMM36 to relax multi-modified structures with high success rates, creating valid training distributions for subsequent rounds.
[Response to W4 & Q4] Empirical Validation Beyond In-Sample Scores and Absolute Molecule Validity
Our validation is not confined to in-sample CHARMM36 scores:
- Independent Explicit-Solvent MD Distributions (Table 3, Page 9): We evaluated generated ensembles against 50 ns explicit-solvent MD in both water and hexane.
- Candidate Validity Metric (Valid@K, Eq. 42, Page 34): To directly address the reviewer's concern that micro-averaged chirality might mask partial stereochemical errors, we evaluate Candidate Validity (Eq. 42, Page 34), which strictly requires 100% correct chiral centers across all residues simultaneously and valid ring closure ().
As shown in Table 3 (Page 9), MuCO2 achieves near-perfect whole-molecule validity, whereas AlphaFold3-based HighFold3 breaks down:
| Dataset / Benchmark | Method | Water @10 | Water Cov.@10 | Div. | Valid@10 (%) |
|---|---|---|---|---|---|
| CycPeptMPDB-MeD | HighFold-MeD2 | 1.519 Å | 1.121 Å | 1.153 Å | 62.7% |
| (Page 9, Table 3) | HighFold3 | 1.500 Å | 1.233 Å | 0.852 Å | 41.5% |
| MuCO2 (Ours) | 1.354 Å | 1.076 Å | 1.177 Å | 100.0% | |
| CycPeptMPDB-Mixed | HighFold3 | 1.275 Å | 0.798 Å | 1.193 Å | 31.4% |
| (Page 9, Table 3) | MuCO2 (Ours) | 1.151 Å | 0.710 Å | 1.241 Å | 100.0% |
- Energy Aggregation Protocol: As formalized in Appendix E.1 (Eq. 33, Page 32), total potential energy scales extensively with peptide length and net charge. To ensure unbiased evaluation, energy comparisons are computed strictly in a pairwise manner across identical target sequences, and then averaged across the dataset.
[Response to W5] Implementation Clarifications: Whole-Peptide Feature Switch & Notations
We have carefully tightened and aligned our descriptions across the main text and appendix:
- Whole-Peptide Feature Switch (Appendix B.1, Page 19, Lines 1011–1015; Eq. 3, Page 4): We confirm that we adopt a whole-peptide feature switch. If a cyclic peptide contains any noncanonical side chain, the representation switches entirely to the projected Uni-Mol2 embeddings () across all residue positions and pairs. Mixing ESM-2 and Uni-Mol2 representations within the same peptide creates latent geometric domain mismatch. As verified in Table 14 (Page 38), this unified Uni-Mol2 representation provides superior chemical and stereochemical grounding:
| Dataset / Benchmark | Embeddings | Success@10 (%) | @10 (kJ/mol) | -RMSD@10 (Å) | Chirality (%) |
|---|---|---|---|---|---|
| HighFold2-Compatible | ESM-2 | 100.00% | -3318.90 | 3.17 Å | 94.19% |
| (Page 38, Table 14) | Uni-Mol2 | 100.00% | -3424.84 | 3.14 Å | 98.81% |
| CycPeptMPDB-Mixed | ESM-2 | 100.00% | 504.39 | 0.64 Å | 92.35% |
| (Page 38, Table 14) | Uni-Mol2 | 100.00% | 447.92 | 0.56 Å | 98.41% |
- Side-Chain Partition Notation ( vs. ): In the main text (Page 3, Line 149), and denote standard canonical versus noncanonical amino acid types. In Appendix B.1 (Page 19, Lines 1017–1025), generalizes to include noncanonical residues that share canonical torsional degrees of freedom parameterized by exocyclic dihedrals (allowing EquiformerV2 neural packing), while designates open-set residues bypassing neural torsions and assembled via template attachment. We have unified this notation in the revised manuscript.
Thank you for your thorough analysis, constructive criticism, and recognition of our model's coherence and breadth. Below is our detailed point-by-point response addressing each of your comments:
and
Corresponding experiments and narrations are updated in revised paper.